FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to the pharmaceutical industry, namely to the use of the agent as a cardioprotective and antiarrhythmic agent. The use of trilithium salt of phospho-ascorbic acid with the general formula Li3C6H6O9P as a cardioprotective and antiarrhythmic agent.
EFFECT: agent is an effective hepatoprotective and antiarrhythmic agent.
1 cl, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
AGENT POSSESSING ANTIARRHYTHMIC ACTION | 2019 |
|
RU2700263C1 |
METHOD FOR SIMULATION OF INCREASED STABILITY OF RAT MYOCARDIUM TO ISCHEMIC-REPERFUSION DAMAGE | 2016 |
|
RU2623727C1 |
AGENT FOR INCREASING RESISTANCE OF HEART TO ARRYTHMOGENIC ACTION OF ISCHAEMIA AND REPERFUSION | 2014 |
|
RU2587783C1 |
CARDIOPROTECTIVE, ANTIARRHYTHMIC ANTI-ISHEMIC AGENT | 2007 |
|
RU2366426C2 |
USE OF TALIPORFIN OR ITS DERIVATIVES IN TREATMENT OF HEART DISEASES, AND ALSO THEIR DERIVATION | 2001 |
|
RU2350326C2 |
AGENT POSSESSING CARDIOPROTECTIVE ACTIVITY | 2019 |
|
RU2699039C1 |
AGENT ELICITING ANTI-ISCHEMIC, HYPOTENSIVE, ANTI- -ARRHYTHMIC AND NOOTROPIC ACTIVITY | 2002 |
|
RU2216322C1 |
COMBINED DRUG PREPARATION CARDIFOL EXHIBITING CARDIOPROTECTIVE, ANTIAGGREGANT AND ANTI-ISCHEMIC ACTION ON CARDIOVASCULAR SYSTEM | 2011 |
|
RU2446806C1 |
N-(2,4,6-TRIMETHYLPHENYLCARBAMOYLMETHYL)-N-ALLYLMORPHOLINIUM BROMIDE SHOWING ANTIISCHEMIC AND ANTIARRHYTHMIC EFFECTS AT ISCHEMIC HEART DISEASE AND A METHOD OF ITS SYNTHESIS | 1997 |
|
RU2105554C1 |
CARDIOPROTECTIVE AGENT | 2020 |
|
RU2743764C1 |
Authors
Dates
2022-11-14—Published
2022-03-28—Filed